Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS Research and Therapy
Published in: AIDS Research and Therapy 1/2012

Open Access 01-12-2012 | Review

Conference highlights of the 5th international workshop on HIV persistence during therapy, 6-9 December 2011, St. Maartin, West Indies

Authors: Mario Stevenson, Nicolas Chomont, Alain Lafeuillade

Published in: AIDS Research and Therapy | Issue 1/2012

Login to get access

Abstract

The December 2011 5th International Workshop on HIV Persistence during Therapy addressed the issue of HIV persistence among 210 scientists from 10 countries involved in the study of HIV reservoirs and the search of an HIV cure. High quality abstracts were selected and discussed as oral or poster presentations. The aim of this review is to distribute the scientific highlights of this workshop outside the group as analyzed and represented by experts in retrovirology, immunology and clinical research.
Literature
1.
Lewin SR, Evans VA, Elliott JH, Spire B, Chomont N: Finding a cure for HIV: will it ever be achievable?. J Int AIDS Soc. 2011, 14: 4- 10.1186/1758-2652-14-4PubMedCentralCrossRefPubMed
2.
Tyagi M, Romerio F: Models of HIV-1 Persistence in the CD4+ T Cell Compartment:Past, Present and Future. Curr HIV Res.2011
3.
Bosque A, Novis C, Martins L, Ramirez P, Famiglietti M, Planelles V: HIV-1 Latency in in vitro Differentiated Central Memory Cells. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 03. Global Antiviral J. 2011, 7 (suppl 2): 4-5. http://​www.​ihlpress.​com/​pdffiles/​AbstractBook_​PW2011_​online.​pdf
4.
Garcia JV: Generation of HIV Latency in BLT Humanized Mice. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 04. Global Antiviral J. 2011, 7 (suppl 2): 5-6.
5.
Clements JE, Russell JN, Gama L, Engle EL, Mankowski JL, Zink MC: The Brain and Spleen are Reservoirs of SIV Infection in Macrophages. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 36. Global Antiviral J. 2011, 7 (suppl 2): 29-30.
6.
Russell JN, Engle EL, Zink MC, Gama L, Clements JE: The Contribution of Splenic Macrophages to SIV Infection and Changes in this Population Following Antiretroviral Treatment. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 05. Global Antiviral J. 2011, 7 (suppl 2): 6-
7.
Trono D, Van Lint C, Rouzioux C: HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science. 2010, 329 (5988): 174-180. 10.1126/science.1191047CrossRefPubMed
8.
Lewin S: The Role of Chemokines in the Establishment of HIV Latency. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 38. Global Antiviral J. 2011, 7 (suppl 2): 30-31.
9.
Yan N, Wheeler LA, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J: The Cytosolic Exonuclease TREX1 Digests HIV Reverse Transcripts to Avoid Triggering an Antiviral Interferon Response in T-cells and Macrophages. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 21. Global Antiviral J. 2011, 7 (suppl 2): 19-
10.
Laguette N, Benkirane M: How Samhd1 May Change our View of Viral Restriction. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 23. Global Antiviral J. 2011, 7 (suppl 2): 20-
11.
Laguette N, Sobhian B, Casartelli N: SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011, 474 (7353): 654-657. 10.1038/nature10117PubMedCentralCrossRefPubMed
12.
Hrecka K, Hao C, Gierszewska M: Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature. 2011, 474 (7353): 658-661. 10.1038/nature10195PubMedCentralCrossRefPubMed
13.
Lahaye X, Silvin A, Satoh T, Conrad C, Littman DR, Manel N: Innate Immunity & Establishment of HIV Reservoirs. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 22. Global Antiviral J. 2011, 7 (suppl 2): 19-20.
14.
O'Doherty U: Relevance of Monitoring HIV viral DNA intermediates in vivo. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 25. Global Antiviral J. 2011, 7 (suppl 2): 21-
15.
Graf EH, Mexas AM, Yu JJ: Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV + patients on and off HAART. PLoS Pathog. 2011, 7: e1001300- 10.1371/journal.ppat.1001300PubMedCentralCrossRefPubMed
16.
Buzon MJ, Seiss K, Weiss R: Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers. J Virol. 2011, 85: 9646-9650. 10.1128/JVI.05327-11PubMedCentralCrossRefPubMed
17.
Buzon MJ, Yang Y, Seiss K, Pereyra F, Yu XG, Lichterfeld M: Increased Susceptibility to CD8 T Cell Mediated Killing Limits the HIV-1 Reservoir in Naïve CD4 T Cells from Elite Controllers. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 28. Global Antiviral J. 2011, 7 (suppl 2): 22-23.
18.
Deeks SG: The Impact of HIV-associated Inflammation on HIV Persistence. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 26. Global Antiviral J. 2011, 7 (suppl 2): 21-
19.
Plaeger SF, Collins BS, Musib R, Deeks SG, Read S, Embry A: Immune Activation in the Pathogenesis of Treated Chronic HIV Disease: A Workshop Summary. AIDS Res Hum Retroviruses. 2011
20.
Yukl S, Shergill AK, McQuaid K: Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010, 24: 2451-2460. 10.1097/QAD.0b013e32833ef7bbPubMedCentralCrossRefPubMed
21.
Hatano H, Hayes TL, Dahl V: A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis. 2011, 203: 960-968. 10.1093/infdis/jiq138PubMedCentralCrossRefPubMed
22.
Chomont N: Immunological Mechanisms Involved in HIV Persistence: Keeping Memory, Keeping HIV. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 27. Global Antiviral J. 2011, 7 (suppl 2): 22-
23.
Vandergeeten C, DaFonseca S, Fromentin R, Sekaly RP, Chomont N: Differential Impact of IL-7 and IL-15 on HIV Reservoir Persistence. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 29. Global Antiviral J. 2011, 7 (suppl 2): 23-
24.
Chirullo B, Sgarbanti R, Lewis MG: Modulation of Oxidative Stress Induces Apoptosis in Long-Lived Phenotypes ex vivo. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 30. Global Antiviral J. 2011, 7 (suppl 2): 23-24.
25.
Lewis MG, Dafonseca S, Chomont N: Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS. 2011, 25 (11): 1347-1356. 10.1097/QAD.0b013e328347bd77CrossRefPubMed
26.
Savarino A, Mai A, Norelli S: "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology. 2009, 6: 52- 10.1186/1742-4690-6-52PubMedCentralCrossRefPubMed
27.
Kuritzkes D: Designing Clinical Trials for HIV-1 Eradication. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 37. Global Antiviral J. 2011, 7 (suppl 2): 30-
28.
Lori F, Jessen H, Lieberman J: Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis. 1999, 180: 1827-1832. 10.1086/315113CrossRefPubMed
29.
Strain MC, Little SJ, Daar ES: Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis. 2005, 191: 1410-1418. 10.1086/428777CrossRefPubMed
30.
Hocqueloux L, Prazuck T, Avettand-Fenoel V: Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS. 2010, 24: 1598-1601. 10.1097/QAD.0b013e32833b61baCrossRefPubMed
31.
Markowitz M, Evering T, Garmon D, Caskey M: A Randomized, Open-Label Trial of 5-Drug versus Standard 3-Drug PI-based cART Initiated During Acute and Early Infection: 96-Week Results. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 31. Global Antiviral J. 2011, 7 (suppl 2): 25-26.
32.
Ananworanich J, Vandergeeten C, Schuetz A, Sereti I: The Effect of Mega-HAART and HAART Instituted During Fiebig I to IV Acute HIV Infection on HIV Reservoir Size and Gut T cells. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 32. Global Antiviral J. 2011, 7 (suppl 2): 26-27.
33.
Zack JA: Thoughts on Elimination of Latent HIV Reservoirs. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 11. Global Antiviral J. 2011, 7 (suppl 2): 11-
34.
Kovochich M, Marsden MD, Zack JA: Activation of latent HIV using drug-loaded nanoparticles. PLoS One. 2011, 6 (4): e18270- 10.1371/journal.pone.0018270PubMedCentralCrossRefPubMed
35.
Margolis D, Archin NM, Kuruc JD: The Effect of Vorinostat on Latent HIV-1 Expression in vivo: Preliminary Findings from a Clinical Study in ART-suppressed HIV-1-infected Patients. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 40. Global Antiviral J. 2011, 7 (suppl 2): 31-32.
36.
37.
Huang L, Lee L, Chen CH: Picomolar Dichotomous Activity of Gnidimacrin against HIV-1 Latent Infection. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 43. Global Antiviral J. 2011, 7 (suppl 2): 34-35.
38.
Huang L, Ho P, Yu J, Zhu L, Lee KH, Chen CH: Picomolar dichotomous activity of gnidimacrin against HIV-1. PLoS One. 2011, 6 (10): e26677- 10.1371/journal.pone.0026677PubMedCentralCrossRefPubMed
39.
Sigal A, Kim JT, Balazs AB: Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature. 2011, 477 (7362): 95-98. 10.1038/nature10347CrossRefPubMed
40.
Schacker T, Stevenson M, Fletcher C: Anatomic HIV Reservoirs. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 35. Global Antiviral J. 2011, 7 (suppl 2): 28-29.
41.
Cohen J: Tissue Says Blood Is Misleading, Confusing HIV Cure Efforts. Science. 2011, 334 (6063): 1614- 10.1126/science.334.6063.1614CrossRefPubMed
42.
Tebas P, Stein D, Wang S: A Single Infusion of Zinc Finger Nuclease (ZFN) CCR5 Modified Autologous CD4 T-cells Correlates with Increases CD4 Counts and Effects on Viral Load in Aviremic HIV-infected Subjects. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 45. Global Antiviral J. 2011, 7 (suppl 2): 36-37.
43.
Jerome KR, Mintzer E, Baker D, Schiffer JT, Aubert M: Direct Targeting of Integrated HIV Sequences Using Engineered Homing Endonucleases. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 48. Global Antiviral J. 2011, 7 (suppl 2): 37-
Metadata
Title
Conference highlights of the 5th international workshop on HIV persistence during therapy, 6-9 December 2011, St. Maartin, West Indies
Authors
Mario Stevenson
Nicolas Chomont
Alain Lafeuillade
Publication date
01-12-2012
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2012
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/1742-6405-9-7

Other articles of this Issue 1/2012

AIDS Research and Therapy 1/2012 Go to the issue

Research

Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand

Research

Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study

Research

Predictors of mortality among HIV infected patients taking antiretroviral treatment in Ethiopia: a retrospective cohort study

Short report

Tuberculosis associated immune reconstitution inflammatory syndrome in patients infected with HIV: meningitis a potentially life threatening manifestation

Short report

Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure

Research

HIV serostatus disclosure is not associated with safer sexual behavior among HIV-positive men who have sex with men (MSM) and their partners at risk for infection in Bangkok, Thailand
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits